Advertisement
QURE 外匯新聞
UniQure Says FDA Clears IND Application For AMT-191 Gene Therapy For Fabry Disease
Gene therapy company uniQure N.V. (QURE) announced Wednesday that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-191, the Company's gene therapy candidate for Fabry disease.
RTTNews
|
627天前
UniQure To Sell Royalty Interest In HEMGENIX For Up To $400 Mln
Gene therapy company uniQure N.V. (QURE) announced Monday it has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of HEMGENIX (etranacogene dezaparvovec-drbl) to HealthCare Royalty (HCRx) and Sagard Healthcare for a gross purchase price of up to $400 million in cash.
RTTNews
|
825天前
